Bold opening: A genetic clue could change how we fight inflammatory bowel disease today, dramatically shifting outcomes for thousands of patients. But here’s where it gets controversial: genetics is only part of the story, and matching treatment to the individual is still a work in progress.
Approximately 60,000 Danes live with chronic inflammatory bowel disease, a range that runs from mild discomfort to a harrowing trajectory that may require surgery and a stoma. The daily fear of urgent toilet needs can make leaving home feel like a major hurdle for many people.
A central challenge in IBD care is that clinicians cannot reliably predict how the disease will progress for any given patient. That means some people are treated too aggressively, while others aren’t treated soon enough, and crucial windows for early intervention can be missed before the intestine sustains irreversible damage.
A new Danish study from the DNRF Center of Excellence PREDICT at Aalborg University suggests that we can forecast, at diagnosis, who is likely to experience a severe disease course.
Researchers found a link between higher genetic risk for IBD and a greater likelihood of a severe disease trajectory. In practical terms, a person’s genetic profile at the outset could indicate who may need closer monitoring and potentially more assertive early therapy.
This work represents an important step toward truly personalized treatment.
How the study was done
The team combined national registry data with clinical records and material from Denmark’s National Biobank, analyzing almost 8,300 individuals with chronic inflammatory bowel disease. The findings were published in the prestigious international journal Gastroenterology.
Lead author Marie Vibeke Vestergaard, whose PhD work at PREDICT encompassed the project, notes: “Today, there is no cure for chronic inflammatory bowel disease. We can control it with medications or, in some cases, remove the affected section of the intestine. Yet many patients suffer relapses and require changes in therapy, and the disease can follow very different paths.” She adds, “What we need is a reliable clinical tool to tailor the right strategy for each person. These results are among the first real steps toward personalized care.”
A missing piece: biological markers
The observed genetics-severity link is supported by a prior study from the same group, which highlighted a specific gene, HLA-DRB1*01:03, that significantly increases the risk that ulcerative colitis patients will need major surgery. While promising, these insights are just the beginning. There is a clear need for deeper knowledge about biological markers that can guide prevention and management of disease progression.
To move forward, the researchers will pursue follow-up studies to determine which medications and treatment approaches work best for defined subgroups of patients.
“ Genetics is one factor among many that influence both the development and course of IBD,” says Vestergaard. “We will continue exploring other contributors to refine risk prediction and ultimately help clinicians offer more precise, effective treatments so that more patients experience a milder disease course.”
Key facts about chronic inflammatory bowel disease
- Inflammatory bowel disease (IBD) is commonly categorized into Crohn’s disease and ulcerative colitis, both of which involve chronic inflammation—Crohn’s can affect any part of the GI tract, while ulcerative colitis is limited to the colon.
- Around 2,700 Danes are diagnosed each year, with the majority in their 20s to 40s; about 60,000 Danes live with chronic IBD, and incidence is rising. By comparison, roughly 32,000 Danes have type 1 diabetes.
Where to read more
The PREDICT study has been published in Gastroenterology and is accessible in full here: https://doi.org/10.1053/j.gastro.2025.09.018
Public release notes: This material originates from the studying organization and may reflect standing at the time of release. Mirage.News provides this content as written by the authors and does not endorse positions beyond the authors’ statements. View the full article here: https://www.miragenews.com/heritability-insights-boost-chronic-bowel-1628612/
Follow-up question to readers: Do you think genetic testing should become a standard part of initial IBD assessments, even if it doesn’t guarantee perfect prediction? What aspects of personalized care do you think would matter most to patients and families in the coming years?
